Tarlatamab in DLL3-Expressing Tumors Including NEN • ClinicalTrials.gov： NCT06788938 • Dr. Goldman
Join Dr. Jonathan Goldman, medical oncologist and clinical trial specialist at UCLA, as he provides an in-depth overview of a new clinical trial investigating tarlatumab, a DLL3-targeted bispecific T-cell engager designed to treat a wide range of neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). In this talk, Dr. Goldman explains: What DLL3 is and why it is an important target found on many neuroendocrine tumors How tarlatumab works by connecting T-cells to tumor cells to trigger a focused immune response Why DLL3-positive tumors—including small cell lung cancer, lung carcinoids, thymic tumors, pancreatic NETs, gastrointestinal NETs, prostate NEC, Merkel cell carcinoma, and others—may respond to this therapy The structure of the L10 Clinical Trial, now in Stage 2 and enrolling across all University of California cancer centers What patients can expect from the tarlatumab treatment schedule and dosing Potential side effects such as cytokine release syndrome, fatigue, constipation, loss of taste, neurologic symptoms, and tumor lysis syndrome Dr. Goldman highlights both the promise of DLL3-targeted therapies and the ongoing need to understand how DLL3 expression levels relate to patient response.
Join Dr. Jonathan Goldman, medical oncologist and clinical trial specialist at UCLA, as he provides an in-depth overview of a new clinical trial investigating tarlatumab, a DLL3-targeted bispecific T-cell engager designed to treat a wide range of neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). In this talk, Dr. Goldman explains: What DLL3 is and why it is an important target found on many neuroendocrine tumors How tarlatumab works by connecting T-cells to tumor cells to trigger a focused immune response Why DLL3-positive tumors—including small cell lung cancer, lung carcinoids, thymic tumors, pancreatic NETs, gastrointestinal NETs, prostate NEC, Merkel cell carcinoma, and others—may respond to this therapy The structure of the L10 Clinical Trial, now in Stage 2 and enrolling across all University of California cancer centers What patients can expect from the tarlatumab treatment schedule and dosing Potential side effects such as cytokine release syndrome, fatigue, constipation, loss of taste, neurologic symptoms, and tumor lysis syndrome Dr. Goldman highlights both the promise of DLL3-targeted therapies and the ongoing need to understand how DLL3 expression levels relate to patient response.